Liposomal irinotecan is an intravenous topoisomerase inhibitor that is approved in combination with fluorouracil and leucovorin for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) after disease progression following gemcitabine therapy. Read more . . .
In a real-world study, dose reductions (DRs) of liposomal irinotecan (Onivyde) were effective and associated with improved clinical outcomes in the treatment of pancreatic cancer.